PDS Biotechnology (NASDAQ:PDSB) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

PDS Biotechnology (NASDAQ:PDSB) released its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08, Yahoo Finance reports. During the same period last year, the company posted ($0.37) earnings per share.

PDS Biotechnology Stock Performance

PDSB traded up $0.25 on Thursday, reaching $3.27. The company had a trading volume of 122,355 shares, compared to its average volume of 715,656. The company’s fifty day moving average is $3.26 and its 200 day moving average is $3.91. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.56 and a current ratio of 4.56. The stock has a market cap of $119.94 million, a P/E ratio of -2.22 and a beta of 1.91. PDS Biotechnology has a fifty-two week low of $2.53 and a fifty-two week high of $6.85.

Wall Street Analysts Forecast Growth

PDSB has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of PDS Biotechnology in a report on Thursday, May 9th. B. Riley lowered their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.